Overview

The Use of Atropine 0.01% in the Prevention and Control of Myopia (ATOM3)

Status:
Recruiting
Trial end date:
2023-05-02
Target enrollment:
Participant gender:
Summary
Study of low dose atropine in preventing the onset and progression of myopia in high risk children with pre-myopia or low-myopia.
Phase:
Phase 3
Details
Lead Sponsor:
Singapore National Eye Centre
Collaborator:
National Medical Research Council (NMRC), Singapore
Treatments:
Atropine